- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04000061
Heart Failure-USB: Prediction and Progression
April 9, 2025 updated by: University Hospital, Basel, Switzerland
This retrospective cohort study is to identify triggers of heart failure (HF) development and drivers of HF progression as well as the underlying cardiac disease (phenotype) to identify patients at risk and predict the clinical course of the disease.
Data of patients who were hospitalized during the years 2010-2023 with acute coronary syndrome (ACS) and/ or with acute heart failure (AHF) will be collected and analyzed.
In a subgroup cohort efficacy and safety of digoxin in patients with acute heart failure triggered by tachyarrhythmia will be evaluated.
Study Overview
Status
Recruiting
Intervention / Treatment
Study Type
Observational
Enrollment (Estimated)
6000
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Contact
- Name: Christian Müller, Prof. Dr.
- Phone Number: 0041 6132 86 549
- Email: Christian.mueller@usb.ch
Study Contact Backup
- Name: Fiona Nafaa, MD
- Phone Number: +41 61 32 87747
- Email: fiona.nafaa@usb.ch
Study Locations
-
-
-
Basel, Switzerland, 4031
- Recruiting
- Cardiology, University Hospital Basel
-
Contact:
- Christian Mueller, Prof. Dr.
- Phone Number: +41 61 32 86 549
- Email: Christian.mueller@usb.ch
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years and older (Adult, Older Adult)
Accepts Healthy Volunteers
No
Sampling Method
Probability Sample
Study Population
Patients that were hospitalized at the Universitätsspital Basel/ Switzerland with the diagnosis of ACS or AHF during the years 2010 - 2023
Description
Inclusion Criteria:
- Patients hospitalized with a primary diagnosis of ACS
- Patients hospitalized with a primary or secondary diagnosis of AHF
Exclusion Criteria:
- Existence of a documented statement of the patient against the scientific use of clinical data
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
Cohorts and Interventions
Group / Cohort |
Intervention / Treatment |
|---|---|
|
acute coronary syndrome (ACS)
Outcome information (all-cause death, heart failure (HF) hospitalizations) of patients hospitalized with a primary diagnosis of ACS is analyzed.
|
data generated by medical review include Medical history, Medications at presentation, during hospitalization and at discharge, New York Heart Association (NYHA) class, Killip class, Electrocardiographic (ECG) data, echocardiographic data, Interventions (Percutaneous Coronary Intervention (PCI), Coronary Artery Bypass Graft (CABG), Implantable Cardioverter Defibrillator (ICD) implantation, Cardiac Resynchronization Therapy (CRT) Implantation), Outcome Information: all-cause death, HF hospitalizations
data generated by direct IT export include Anthropometric data (age, sex, height, weight), Vital signs, Laboratory data
|
|
acute heart failure (AHF)
Outcome information (all-cause death, heart failure (HF) hospitalizations) of patients hospitalized with a primary or secondary diagnosis of AHF is analyzed.
|
data generated by medical review include Medical history, Medications at presentation, during hospitalization and at discharge, New York Heart Association (NYHA) class, Killip class, Electrocardiographic (ECG) data, echocardiographic data, Interventions (Percutaneous Coronary Intervention (PCI), Coronary Artery Bypass Graft (CABG), Implantable Cardioverter Defibrillator (ICD) implantation, Cardiac Resynchronization Therapy (CRT) Implantation), Outcome Information: all-cause death, HF hospitalizations
data generated by direct IT export include Anthropometric data (age, sex, height, weight), Vital signs, Laboratory data
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
number of all-cause death
Time Frame: 1 to 8 years after hospitalization
|
number of all-cause death in patients hospitalized with ACS and AHF during the years 2010-2023.
|
1 to 8 years after hospitalization
|
|
number of HF hospitalizations
Time Frame: 1 to 8 years after hospitalization
|
number of new HF hospitalizations in patients hospitalized with ACS and AHF during the years 2010-2023
|
1 to 8 years after hospitalization
|
|
number of cardiovascular death
Time Frame: 1 to 8 years after hospitalization
|
number of cardiovascular death in patients hospitalized with ACS and AHF
|
1 to 8 years after hospitalization
|
|
number of cardiovascular hospitalizations
Time Frame: 1 to 8 years after hospitalization
|
number of cardiovascular hospitalizations
|
1 to 8 years after hospitalization
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Investigators
- Principal Investigator: Christian Müller, Prof. Dr., Cardiology University Hospital Basel
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
June 13, 2019
Primary Completion (Estimated)
December 31, 2026
Study Completion (Estimated)
December 31, 2026
Study Registration Dates
First Submitted
June 25, 2019
First Submitted That Met QC Criteria
June 25, 2019
First Posted (Actual)
June 27, 2019
Study Record Updates
Last Update Posted (Actual)
April 10, 2025
Last Update Submitted That Met QC Criteria
April 9, 2025
Last Verified
April 1, 2025
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 2019-00956; me19Mueller
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.